Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform, Verisome®.
IBI's Verisome® drug delivery technology is the most advanced, yet simplest system for controlling the release of intraocular therapeutic agents in the eye for extended periods of time. Its unmatched versatility can support products individually formulated to meet the specific clinical requirements of a given active agent targeting a specific ophthalmic disease.
IBI's current portfolio consists of seven (7) proprietary products, all targeting significant unmet ophthalmic medical needs. Over 300 patients have been administered products based on the Verisome® drug delivery technology.
The lead pipeline product using the Verisome® technology is IBI-10090 which is being developed as a biodegradable therapeutic for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery.
IBI-10090 will be Icon’s first … Read more
Icon Bioscience, Inc. will pursue corporate partnerships and out-licensing agreements of its Verisome® technology in limited opportunistic circumstances. IBI is currently involved with multiple collaborations involving a wide variety of new chemical entities targeting … Read More
Contact Icon Bioscience, Inc.
David S. Tierney, M.D.
Chief Executive Officer
1253 Reamwood Avenue
Sunnyvale, California 94089
Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089 | 650-369-4049